Shares of Xencor, Inc. (NASDAQ:XNCR) have earned an average recommendation of “Hold” from the nine research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $28.00.

Several equities research analysts recently weighed in on the company. Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Xencor in a report on Tuesday, August 8th. BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Xencor in a report on Friday, June 16th.

Xencor (NASDAQ XNCR) traded down 0.16% during trading on Friday, reaching $24.79. The company’s stock had a trading volume of 249,273 shares. The stock’s market cap is $1.16 billion. The company’s 50 day moving average price is $22.05 and its 200-day moving average price is $22.47. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Equities analysts forecast that Xencor will post ($1.17) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/xencor-inc-xncr-receives-average-rating-of-hold-from-brokerages/1618356.html.

In other Xencor news, major shareholder John S. Stafford III acquired 25,000 shares of the stock in a transaction dated Wednesday, August 16th. The stock was purchased at an average cost of $20.96 per share, with a total value of $524,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder John S. Stafford III acquired 27,000 shares of the stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $21.13 per share, with a total value of $570,510.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 215,551 shares of company stock valued at $4,386,916. Corporate insiders own 4.03% of the company’s stock.

Several hedge funds have recently bought and sold shares of XNCR. Bank of New York Mellon Corp raised its position in shares of Xencor by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 198,988 shares of the biopharmaceutical company’s stock worth $4,759,000 after acquiring an additional 27,109 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in Xencor by 0.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 209 shares in the last quarter. Prudential Financial Inc. bought a new stake in Xencor in the 1st quarter valued at about $600,000. Clinton Group Inc. increased its position in Xencor by 4.6% in the 1st quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock valued at $382,000 after buying an additional 700 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in Xencor by 2,826.5% in the 1st quarter. Victory Capital Management Inc. now owns 28,533 shares of the biopharmaceutical company’s stock valued at $682,000 after buying an additional 27,558 shares in the last quarter. 76.92% of the stock is owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.